Inicio・Lista de Acciones・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Cerrado

4.13 -2.82

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

4.04

Máximo

4.3

Métricas clave
By Trading Economics
Ingresos	-42M -78M
BPA	-0.59
Empleados	106
EBITDA	-42M -77M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+88.56% upside

Dividendos
By Acuity
Próximas Ganancias	6 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-34M 297M
Apertura anterior	6.95
Cierre anterior	4.13

Zentalis Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 ago 2026, 23:56 UTC

Zions Bancorporation shares are higher in after-market hours, continuing gains amid broader market dynamics influenced by recent U.S. Consumer Price Index data.

12 ago 2026, 23:56 UTC

News

Allegro Microsystems shares rose in after-market trading following Benchmark's initiation of coverage with a Buy rating. The stock closed at $42.52.

12 ago 2026, 23:56 UTC

JinkoSolar shares are higher in after-market trading, reflecting a modest uptick since Wednesday's close amid U.S. Consumer Price Index data release.

12 ago 2026, 23:56 UTC

Yum Brands Inc. shares are higher in after-market trading, reflecting routine performance amid broader market dynamics following the release of U.S. Consumer Price Index data.

12 ago 2026, 23:56 UTC

Griffon Corp shares are higher in after-market hours, supported by U.S. Consumer Price Index data easing concerns over Federal Reserve interest rate hikes.

12 ago 2026, 23:56 UTC

Social Media

News

STAAR Surgical shares are lower in after-market hours following an EPS miss, despite reporting second-quarter net sales of $93.5 million, a 111% increase.

12 ago 2026, 23:56 UTC

MasTec Inc shares are higher in after-market hours, recovering from an earlier dip. The movement aligns with broader market dynamics following U.S. CPI data.

12 ago 2026, 23:56 UTC

Molina Healthcare Inc shares are higher in after-market hours, following the release of U.S. Consumer Price Index data that met expectations.

12 ago 2026, 23:56 UTC

Ionis Pharmaceuticals Inc. shares are lower in after-market trading, despite remaining above their 20-day moving average and within the upper range for the month.

12 ago 2026, 23:56 UTC

ETF Constituents

Vanguard FTSE Emerging Markets ETF shows modest after-market gains, supported by Taiwan Semiconductor and Pinduoduo. The ETF is near its one-month range's upper end.

12 ago 2026, 23:56 UTC

Ares Capital Corp shares are lower in after-market hours, continuing a three-session decline amid market volatility following U.S. Consumer Price Index data release.

12 ago 2026, 23:56 UTC

DaVita Inc shares are lower in after-market trading following a session peak. The stock remains under pressure, trading below its 20-day moving average.

12 ago 2026, 23:56 UTC

ETF Constituents

Correlated Moves

VanEck Gold Miners ETF declines in after-market trading, impacted by top holdings including Pan American Silver's drop and slight decreases in silver prices.

12 ago 2026, 23:56 UTC

Chevron Corp shares gained during after-market hours following the release of U.S. Consumer Price Index data, which eased concerns about Federal Reserve interest rate hikes.

12 ago 2026, 23:56 UTC

Social Media

Snowflake Inc. shares advanced in after-market trading, buoyed by U.S. CPI data and positive sentiment in tech sector discussions.

12 ago 2026, 23:56 UTC

Bristol-Myers Squibb Co shares rose in after-market trading following U.S. Consumer Price Index data, easing concerns about aggressive Federal Reserve interest rate hikes.

12 ago 2026, 23:56 UTC

Gogo Inc. shares are higher in after-market trading, following the release of U.S. Consumer Price Index data that met expectations and eased rate hike concerns.

12 ago 2026, 23:56 UTC

Comcast shares declined in after-market trading, following the release of U.S. Consumer Price Index data. The stock remains above its 20-day moving average.

12 ago 2026, 23:56 UTC

elf Beauty Inc. shares are lower in after-market trading, continuing a four-session decline. The stock remains above its 20-day moving average.

12 ago 2026, 23:54 UTC

Ambarella Inc. shares remained roughly flat in after-market hours, with no specific news identified. The stock is positioned above its 20-day moving average.

12 ago 2026, 23:52 UTC

UK House Price Balance Shows Slight Improvement at -0.3%, Indicating Ongoing Market Challenges Despite Optimism for Future Stabilization

12 ago 2026, 23:52 UTC

RBA Holds Cash Rate at 4.35% Amid Inflation Concerns; Assistant Governor Kent's Upcoming Speech Sparks Market Speculation

12 ago 2026, 23:52 UTC

Canada's housing starts data set for release on August 18, following June's decline and amid government initiatives to boost affordable home construction.

12 ago 2026, 23:52 UTC

Australia's Consumer Confidence Report Set for August 18 Amidst Cautious Market Sentiment and Economic Volatility.

12 ago 2026, 23:52 UTC

Australia's Consumer Confidence Index release on August 18, 2026, faces cautious market expectations amid mixed economic signals and ongoing geopolitical tensions.

12 ago 2026, 23:52 UTC

Brazil's Industrial Entrepreneur Confidence Index Expected to Remain Low Amid Economic Uncertainty, Anticipating Continued Pessimism Ahead of August 13 Release.

12 ago 2026, 23:52 UTC

Australia's Investment Lending Data Release on August 14 Expected to Impact Housing Market Insights Amid Cautious Sentiment.

12 ago 2026, 23:52 UTC

Japan's Upcoming Export Data Release on August 19, 2026, Expected to Reflect Trends in High-Tech Products Amid Global Economic Uncertainties.

12 ago 2026, 23:52 UTC

Japan's Upcoming Balance of Trade Data Expected to Show Continued Deficits Amid Rising Imports and Geopolitical Tensions

12 ago 2026, 23:52 UTC

JD.Com Inc. shares are lower in after-hours trading, reversing from an early gain amid broader market trends influenced by recent inflation data.

Comparación entre iguales

Cambio de precio

Zentalis Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

88.56% repunte

Estimación a 12 Meses

Media 7.75 USD 88.56%

Máximo 11 USD

Mínimo 4 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Zentalis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Zentalis Pharmaceuticals Inc Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.